Advertisement
U.S. markets closed
Advertisement

Adocia SA (ADOC.PA)

Paris - Paris Delayed Price. Currency in EUR
8.06+0.13 (+1.64%)
At close: 05:37PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.93
Open7.99
Bid0.00 x 0
Ask0.00 x 0
Day's Range7.99 - 8.46
52 Week Range2.74 - 16.16
Volume170,322
Avg. Volume205,166
Market Cap111.859M
Beta (5Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-2.50
Earnings DateOct 25, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ADOC.PA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Adocia Publishes its Letter to Shareholders

      LYON, France, November 23, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the publication of the November 2023 Letter to Shareholders.

    • Business Wire

      Number of Shares and Voting Rights of ADOCIA as of October 31st, 2023

      LYON, France, November 15, 2023--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with inno

    • Business Wire

      ADOCIA Revealed Promising Preclinical Data on AdoShell® Islets for Cell Therapy of Diabetes

      LYON, France, November 09, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, disclosed additional results on AdoShell® Islets during recent international congresses.